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cedural blood loss was needed in 2 patients. No coronary event occurred
between 48h and discharge, or during follow-up. Local complications oc-
curred in 4 patients (surgical repair 1, blood transfusion 2, false aneurysm
1)
In this early experience, no subacute closure occurred after bailout or elec-
tive stenting using intense antiplatelet therapy. Such an approach appears
safe and may permit much earlier patient discharge.
with external compression and 3 minor hemotomas. Mean hospital stay was
2 ± 2 days.
Conclusions. (1) Protamine given immediately following a successful stent
implantation with optimal stent expansion confirmed by IVUS did not cause
stent thrombosis. 12) The results of this small cohort would support the
feasability of using protamine to facilitate sheath removal and hospital dis-
charge in selected patients after stent implantation assisted by IVUS.
Percutaneous Trans Radial Coronary Stenting
without Coumadin can Reduce Vascular Access
Complications and Hospital Stay
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1741-51 Improved Post Stent Management: High Gain at Low
Risk
P. Buszman, J. Clague, S. Gibbs, N. Buller, C. Knight. P. Groves, U. Sigwart. Royal
Brompton Hospital, Sydnay Straat London UK.
Prolonged hospital stay, sophiscated anticoagulation and a high number of
local puncture site complications are the reasons why coronary stenting, de-
spite its attractive immediate and long term results, is not yet fully accepted.
We have tested in 100 consecutive patients a simplified post implant man-
agement designed to shorten hospital stay without increasing the risk of
subacute thrombosis or bleeding complications. The decision for stenting
was always made during angioplasty. There were no preselected cases. All
patients had suboptimal results due to elastic recoil or type 2 to 3 dissec-
tions. A total of 123 Johnson &Johnson PS-153 stents (24 half stents, 87 full
stents and 12 tandem stents) were implanted using high pressure balloons
with implantation pressures exceeding 14 bar. The mean reference vessel
diameter was 3.2 ± 0.6 mm final balloon size at maximum pressure was 3.4
± 0.3 mm. In 73% of the stent implants a short balloon was used for the final
dilation. Only in 10 patients was the procedure complimented by intravascu-
lar ultrasound. The ACT at the time of implant was 346 ± 48 seconds, no
further intravenous heparin was given. All sheaths were removed the same
day and a FemoStop'" compression device was left in situ at low pressures
for 8 ± 3.5 hours. The patients were discharged on day 1 (48 patients) or 2
(52) on low molecular weight heparin 5,000 units SC for 7 days, self admin-
istered after instruction. Warfarin was started the day of the procedure and
given for 6 weeks and regulated to an INR of 2.5 to 3.5 while the patient was
out of hospital. All patients received Aspirin 75 mg per day and a calcium
antagonist.
There was 1 subacute thrombosis which was successfully treated by
thrombolysis at 16 hours after implant secondary to a non covered distal
dissection. We observed 1 femoral false aneurysm responding to compres-
sion. 1 patient died 10 days after the procedure from late haemorrhage due
to dissection of the iliac artery.
We conclude that a short hospital stay does not increase the risk of throm-
botic and bleeding complications after stenting. Stenting with good primary
result has a extremely low subacute thrombosis rate. Intravenous heparin
after stenting is unnecessary.
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Jean-L. Bouvier, Bertrand Comet. Cliniqua "Las AJpillas~ Marsailla, France
Intravascular ultrasound (IVUS) guiding optimal coronarystent expansion has
been proposed in the prevention of subacute stent thrombosis (SIT) wich
remains the major limitation of coronary stenting. However this strategy, re-
quiring high balloon pressure, enhances the risk of coronary rupture, and
increases the time of procedure. We report our experience of coronary stent-
ing using quantitative coronary analysis (OCA) and ticlopidine regimen (500
mg/day) initiated 3 days before PTCA and given for one month after stenting
without any anticoagulation. From March 1994 to July 1994 among 587 con-
secutive PTCA, 208 patients (63 ± 11 yrs) were successfully stented on 235
lesions with 248 stents (223 Palmaz-Schatz, 25 Gianturco-Roubin). Femoral
approach was used in 98% of cases with 8F (65%) or 6F guiding catheter
(35%). Indications for stenting were elective (70%) or after failed PTCA(30%).
The stents were expanded with a non compliant balloon (final diameter =
3.46 ± 0.42 mm) at 10 bars. OCA results were:
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Prevention of Subacute Occlusion After Coronary
Stenting with Ticlopidine Regimen without
Intravascular Ultrasound Guided Stenting
* p < 0.001
One month major complications included 2 deaths (0.96%1. 2 O-wave
MI (0.96%) and 1 emergency CABG (0.5%). SST during the first month oc-
cured in 1 pt (0.5%). One pt (0.5%) required external compression for false
aneurism and one (0.5%) blood transfusion for gastric hemorrhage.
Conclusion: Pre and post coronary stenting treatment with ticlopidine reg-
imen provides low rate of SST with acceptable vascular bleeding complica-
tions. Routine IVUS utility with this regimen remains uncertain.
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Preliminary Experience Using Protamine to Reverse
Heparin Immediately Following a Successful
Coronary Stent Implantation
Antonio Colombo, Patrick Hall, Shigeru Nakamura, Luigi Maiello, Brenda Hann,
Simonetta Slengino, Giovanni Martini, Leo Fincr. Columbus Hospital, Milan, Italy
Previous reports have documented the safety of the treatment only with an-
tiplatelet therapy and no subsequent anticoagulation following stent implan-
tation with optimal stent expansion confirmed by intravascular ultrasound
(IVUS). More recently, protamine has been used in selected patients after a
successful stent implantation procedure to decrease hematoma formation,
and to facilitate early sheath removal and hospital discharge. Lesions were
selected on the basis of an optimal angiographic and IVUS result and unim-
paired distal runoff. The cohort includes 30 consecutive patients (pts) with 37
lesions (les) that received protamine following a successful stent implanta-
tion. All pts were subsequently treated only with antiplatelet therapy and no
subsequent anticoagulation. The mean age was 58 ± 11. Indication for stent
implantation was elective in 32 les (90%) and emergency for threatened clo-
sure in 5 lesions (10%). Vessel distribution was 15 LAD (41 %1. 15 RCA(41 %),
6 LCX (16%), and 1 Left Main (3%). Lesion location was 22 proximal (59%),
11 mid/distal (41%).51 stents (39 Palmaz-Schatz, 9 Gianturco-Roubin, and 3
Wiktor) were used for afl average of 1.4 ± 0.7 stentsllesion. The protamine
dose was 41 ± 20 (range 12.5 mg to 50 mg). ACT priorto protamine was 300
± 69 (range 185 to 481). Angiographic (AG) and IVUS results are below:
Proximal Lesion Stenosis Distal
Reference or Stent ('!o) Reference
Baseline AG (mm) 3.10 ± 0.50 0.92 ± 0.053 ( 72 ± 16) 298 ± 048
Post Stent AG (mm) 319±042 3.04 ± 048 ( -2 ± 13) 3.06 ± 048
IVUS Lumen (mm2 ) 9.3 ± 3.0 7.6 ± 1.6 7.1 ±24
Jean Fajadet. Christian Jordan, Henrique Carvalho, Bernard Cassagneau,
Gabriel Robert, Jean-Pierre Laurent. Yves Siboni, Jean Marco. Cliniqua Pastaur.
Toulouse, France
Benestent and Stress studies have demonstrated that the significant reduc-
tion of restenosis rate after Palmaz-Schatz stent(S) implantation of de novo
lesions was associated with a longer hospital stay and a higher bleeding
and vascular access complication rate due to the intensive anticoagulation.
Therefore we have studied a new coronary stenting procedure using a 6F
transradial approach and a new protocol based on antiplatelet drug combi-
nation (Aspirin = 250 mg/day ± Ticlopidin 500 mg/day), low molecular weight
heparin and no Coumadin. One hundred and nineteen patients (101 males,
18 females, with a mean age of 61.8 ± 11.6 yrs (32-83) received 154 S in
127 vessels. Stenting was elective in 38% and non elective in 62%. No acute
thrombosis occurred. Two major cardiac events were observed: one pt with
low LVEF (37%1 and 3 vessel disease presented a sudden death 3 days after
non elective LAD stent implantation and one pt had a non O-wave MI due to
a side branch occlusion after non elective stenting. The 118 pts discharged
2.9 ± 1.5 days (1-8 days) after procedure and 75% of them within the first 3
days. Conclusion: Trans radial coronarystenting is a safe and effective proce-
dure. This new stent delivery procedure can certainly reduce vascular access
complications and hospital stay.
There were no acute or subacute stent thrombosis events at 1 month clin-
ical follow up. Vascular complications included 1 pseudoaneuysm treated
